Provided by Tiger Fintech (Singapore) Pte. Ltd.

Invivyd, Inc.

0.7200
-0.0858-10.65%
Post-market: 0.72000.00000.00%16:34 EDT
Volume:1.26M
Turnover:941.55K
Market Cap:86.12M
PE:-0.37
High:0.8300
Open:0.8200
Low:0.7200
Close:0.8058
Loading ...

Invivyd Inc - Vyd2311 Has Favorable Safety and Tolerability

THOMSON REUTERS
·
03 Feb

Invivyd Inc - Positive Phase 1/2 Data for Vyd2311 on Safety and Pharmacokinetics

THOMSON REUTERS
·
03 Feb

Invivyd Inc - Vyd2311 Suitable as Long-Acting Covid-19 Treatment Option

THOMSON REUTERS
·
03 Feb

Invivyd Announces Positive Phase 1/2 Clinical Data for VYD2311, a Monoclonal Antibody Designed to be a Superior Alternative to COVID-19 Vaccination for the Broad Population

GlobeNewswire
·
03 Feb

Invivyd Inc: Reiterates Goal of Near-Term Profitability

THOMSON REUTERS
·
03 Feb

Invivyd Announces Preliminary Fourth Quarter 2024 Financial Results, Strong Revenue Growth, and Reiterates Goal of Near-Term Profitability

GlobeNewswire
·
03 Feb

We Might See A Profit From Invivyd, Inc. (NASDAQ:IVVD) Soon

Simply Wall St.
·
30 Jan

Invivyd Is Maintained at Buy by D. Boral Capital

Dow Jones
·
27 Jan

Invivyd Provides Another Positive Sars-Cov-2 Variant Data Analysis to Satisfy U.S. FDA’s Gating Request for Completing Its Review of Eua Request for Pemgarda™ (Pemivibart) for the Treatment of Mild-to-Moderate Covid-19 in Certain Immunocompromised Patients

THOMSON REUTERS
·
27 Jan

Invivyd Provides Another Positive SARS-CoV-2 Variant Data Analysis to Satisfy U.S. FDA’s Gating Request for Completing Its Review of EUA Request for PEMGARDA™ (pemivibart) for the Treatment of Mild-to-Moderate COVID-19 in Certain Immunocompromised Patients

GlobeNewswire
·
27 Jan

What's Going On With COVID-19 Antibody Developer Invivyd Stock On Friday?

Benzinga
·
11 Jan

Invivyd Is Maintained at Buy by D. Boral Capital

Dow Jones
·
10 Jan

Invivyd announces continued neutralizing activity of PEMGARDA

TIPRANKS
·
10 Jan

Invivyd Inc - No Meaningful Change to Pemgarda Neutralization Activity Expected

THOMSON REUTERS
·
10 Jan

Invivyd Announces Continued Neutralizing Activity of Pemgarda™ (Pemivibart) Against Dominant Sars-Cov-2 Variant Xec

THOMSON REUTERS
·
10 Jan

BRIEF-Invivyd Inc Receives Deficiency Letter From Nasdaq

Reuters
·
28 Dec 2024